Showing 6721-6730 of 8842 results for "".
- Analysis: Lebrikizumab Viable Dupilumab Alternative for Moderate-to-Severe ADhttps://practicaldermatology.com/news/analysis-lebrikizumab-viable-dupilumab-alternative-moderate-severe-ad/2468484/Lebrikizumab is a viable alternative for patients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab due to inadequate response, inability to tolerate the drug, or other reasons, according to a new study presented at the Fall Clini
- Dupilumab Improves Chronic Spontaneous Urticaria Symptomshttps://practicaldermatology.com/news/dupixent-improves-chronic-spontaneous-urticaria-symptoms/2468471/Dupixent® (dupilumab) significantly reduced itch and hive activity in patients with chronic spontaneous urticaria, according to phase 3 trial data presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts. In a pre
- Study Backs CP-GEP Tests’ Accuracyhttps://practicaldermatology.com/news/study-backs-cp-gep-tests-accuracy/2468469/Patients with clinically node-negative primary cutaneous melanoma undergoing sentinel lymph node biopsies (SLNBs) who were classified as “high risk” according to CP-GEP tests were approximately three times more likely to be SLN positive, according to data presented October 13 at the Society of Me
- Study: Roflumilast cream 0.15% Significantly Reduces Itch, Improves Quality of Lifehttps://practicaldermatology.com/news/study-roflumilast-cream-015-significantly-reduces-itch-improves-quality-life/2468468/New data show that ZORYVE® (Roflumilast) cream 0.15% rapidly alleviates symptoms of atopic dermatitis (AD) and significantly improves patient-reported outcomes, including daily activity, sleep, and emotional well-being, according to Arcutis. The manufacturer announced in a pres
- Systematic Review Explores Thiamidol’s Impact on Hyperpigmentationhttps://practicaldermatology.com/news/systematic-review-explores-thiamidols-impact-on-skin-discoloration/2468460/Data from a recent systematic review of 14 clinical studies shows topical isobutylamido thiazolyl resorcinol (ITR) provides statistically significant improvement in various types of hyperpigmentation, including melasma, post-inflammatory hyperpigmentation (PIH), and UV-induced hyperpigmentation.<
- READY-4: Sustained and Safety Efficacy of RelabotulinumtoxinAhttps://practicaldermatology.com/news/ready-4-sustained-and-safety-efficacy-relabotulinumtoxina/2468443/New results from the phase III READY-4 trial presented at the 2024 ASDS Annual Meeting demonstrate the long-term safety and sustained efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) for the treatment of moderate-to-severe frown lines and crow’s feet. The multicenter, open-label REA
- ZORYVE Foam Approved in Canada for Seborrheic Dermatitishttps://practicaldermatology.com/news/zoryve-foam-approved-canada-seborrheic-dermatitis/2468434/Health Canada has approved ZORYVE (roflumilast) foam 0.3% for treating seborrheic dermatitis in individuals aged nine and older, according to a press release from Arcutis. The approval makes ZORYVE the first new topical treatment for the condition approved in Canada in over 20 years. The a
- World Hair Transplant Repair Day Set for November 11https://practicaldermatology.com/news/world-hair-transplant-repair-day-set-november-11/2468428/The International Society of Hair Restoration Surgery (ISHRS) will host its annual “World Hair Transplant Repair Day” on November 11, part of the ISHRS’s Fight the FIGHT (an acronym for Fight the Fraudulent, Illicit, and Global Hair Transplants) global consumer awareness campaign designed to educ
- FDA Clears Accure Laser System for Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-accure-laser-system-acne-vulgaris/2468432/The US Food and Drug Administration (FDA) cleared the Accure Laser System for the long-term treatment of patients with mild-to-severe inflammatory acne vulgaris, according to a press release from Accure Acne, Inc. "This achievement cannot be overstated," Acclure Acne co-founder, chairman o
- Cetaphil Launches Rebrand with Debut of ‘For Everyone’s Sensitive Skin’ Campaignhttps://practicaldermatology.com/news/cetaphil-launches-rebrand-with-debut-of-for-everyones-sensitive-skin-campaign/2468433/A popular skincare line debuts “For Everyone’s Sensitive Skin” campaign as part of a rebrand. Cetaphil announced a complete brand “restage,” in a press release earlier this week. The brand is revamping its 77-year-old image with a bold, refreshed visual upgrade. The goal of the rebrand is